Pollon Life, a Chinese
biotech company backed by Jack Ma’s Yunfeng Capital, has confidentially filed for a Hong Kong IPO that could raise about USD 300 million. The firm, maker of China’s first approved stem cell drug, is working with CCB International, CICC, and UBS on the deal.